Scientists track patients after revolutionary Gene-Editing treatment for blood disorder
NCT ID NCT06479616
Summary
This study follows five patients with beta-thalassemia for two years after they received an experimental gene therapy called CS-101. The goal is to monitor the long-term safety of the treatment and see if patients remain free from needing blood transfusions. Researchers will track any side effects and measure how well the gene-edited cells continue to work over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 201102, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.